Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H1 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310006 .
Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 9, 32, 26, 2, 113, 34 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 32 and 5 molecules, respectively.
Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/type-1-diabetes-juvenile-diabetes-pipeline-review-h1-2017 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310006 .
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AiCuris GmbH & Co KG
Amarantus Bioscience Holdings Inc
Amarna Therapeutics BV
apceth Biopharma GmbH
Araim Pharmaceuticals Inc
Argos Therapeutics Inc
Astellas Pharma Inc
Atlantic Bio Sci LLC
Boehringer Ingelheim GmbH
Caladrius Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dance Biopharm Inc
Denceptor Therapeutics Ltd
Diabetology (Products) Ltd
DiaMedica Therapeutics Inc
Diamyd Medical AB
Diasome Pharmaceuticals Inc
Dompe Farmaceutici SpA
Eli Lilly and Company
Ensol Biosciences Inc
Escape Therapeutics Inc
Fate Therapeutics Inc
Generex Biotechnology Corp
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
Ixchel Pharma LLC
Johnson & Johnson
Kasiak Research Pvt Ltd
KPI Therapeutics Inc
Lexicon Pharmaceuticals Inc
Ligand Pharmaceuticals Inc
Lonestar Heart Inc
Medestea Research & Production SpA
Melior Discovery Inc
Merck & Co Inc
Meridigen Biotech Co Ltd
Mitsubishi Tanabe Pharma Corp
Novo Nordisk A/S
Noxxon Pharma AG
Oramed Pharmaceuticals Inc
Paras Biopharmaceuticals Finland Oy
Parvus Therapeutics Inc
Pathfinder Cell Therapy Inc
PharmaCyte Biotech Inc
Prometheon Pharma LLC
Purzer Pharmaceutical Co Ltd
RedHill Biopharma Ltd
Selecta Biosciences Inc
Semma Therapeutics Inc
Sevion Therapeutics Inc
Thermalin Diabetes LLC
Transgene Biotek Ltd
Traverse Biosciences Inc
United Therapeutics Corp
Zealand Pharma AS
Zensun (Shanghai) Sci & Tech Co Ltd
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact firstname.lastname@example.org